Literature DB >> 11431196

Chronic renal failure, end-stage renal disease, and peritoneal dialysis in Gitelman's syndrome.

L Bonfante1, P A Davis, M Spinello, A Antonello, A D'Angelo, A Semplicini, L Calò.   

Abstract

The chronic state of hypovolemia, hypotension, and hypokalemia found in Bartter's syndrome has been shown to lead to a chronic nephropathy, which then can progress toward end-stage renal disease and dialysis. This progression, however, has never been reported for Gitelman's syndrome, a variant of Bartter's syndrome that shows a milder clinical picture. This report is the first to document this progression (ie, the development of end-stage renal disease in Gitelman's syndrome) as well as the first report of the use of peritoneal dialysis in either Bartter's syndrome or Gitelman's syndrome. The clinical course highlights the importance of and the need for careful control of hemodynamic status in these patients to slow the progression of renal injury. The hemodynamic alterations that characterize Bartter's syndrome and Gitelman's syndrome patients suggest that for patients requiring renal replacement therapy, peritoneal dialysis is a more appropriate treatment because of its less severe impact on these parameters.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11431196     DOI: 10.1053/ajkd.2001.25210

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  15 in total

Review 1.  Thiazide effects and adverse effects: insights from molecular genetics.

Authors:  David H Ellison; Johannes Loffing
Journal:  Hypertension       Date:  2009-06-29       Impact factor: 10.190

2.  Focal segmental glomerulosclerosis in association with Gitelman syndrome.

Authors:  Mevlut Ceri; Selman Unverdi; Mustafa Altay; Hatice Unverdi; Ilhan Kurultak; Rahmi Yılmaz; Arzu Ensari; Murat Duranay
Journal:  Int Urol Nephrol       Date:  2010-07-14       Impact factor: 2.370

3.  Differential diagnosis for chronic hypokalaemia.

Authors:  Laura Stimson; Tim Reynolds
Journal:  BMJ Case Rep       Date:  2018-06-05

4.  C1q nephropathy in association with Gitelman syndrome: a case report.

Authors:  Coral Hanevold; Ayesa Mian; Rory Dalton
Journal:  Pediatr Nephrol       Date:  2006-09-06       Impact factor: 3.714

5.  Clinical and Genetic Characterization of Patients with Bartter and Gitelman Syndrome.

Authors:  Viviana Palazzo; Valentina Raglianti; Samuela Landini; Luigi Cirillo; Carmela Errichiello; Elisa Buti; Rosangela Artuso; Lucia Tiberi; Debora Vergani; Elia Dirupo; Paola Romagnani; Benedetta Mazzinghi; Francesca Becherucci
Journal:  Int J Mol Sci       Date:  2022-05-18       Impact factor: 6.208

6.  Two novel genotypes of the thiazide-sensitive Na-Cl cotransporter (SLC12A3) gene in patients with Gitelman's syndrome.

Authors:  Noriko Aoi; Tomohiro Nakayama; Yoshiko Tahira; Akira Haketa; Minako Yabuki; Tadataka Sekiyama; Chie Nakane; Hiroaki Mano; Hideomi Kawachi; Naoyuki Sato; Masayoshi Soma; Kouichi Matsumoto
Journal:  Endocrine       Date:  2007-04       Impact factor: 3.633

7.  Gitelman syndrome.

Authors:  Patricia Cotovio; Cristina Silva; Nuno Oliveira; Fátima Costa
Journal:  BMJ Case Rep       Date:  2013-04-11

8.  Gitelman syndrome: when will it turn into Gitelman disease?

Authors:  Peter Gross
Journal:  Pediatr Nephrol       Date:  2003-05-01       Impact factor: 3.714

Review 9.  Gitelman syndrome.

Authors:  Nine V A M Knoers; Elena N Levtchenko
Journal:  Orphanet J Rare Dis       Date:  2008-07-30       Impact factor: 4.123

10.  A novel compound heterozygous variant of the SLC12A3 gene in Gitelman syndrome pedigree.

Authors:  Yixin Chen; Ziyi Zhang; Xihua Lin; Qianqian Pan; Fenping Zheng; Hong Li
Journal:  BMC Med Genet       Date:  2018-01-29       Impact factor: 2.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.